1
|
Gomes DM, Meirelles LMA, Araujo PM, de Sousa RWR, Ferreira PMP, Gutierrez SJC, de Medeiros MDGF, Raffin FN. Improving Riparin-A Dissolution through a Laponite Based Nanohybrid. Pharmaceutics 2023; 15:2136. [PMID: 37631350 PMCID: PMC10458571 DOI: 10.3390/pharmaceutics15082136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 07/25/2023] [Accepted: 08/08/2023] [Indexed: 08/27/2023] Open
Abstract
(1) Background: Riparin-A presents several pharmacological activities already elucidated, such as antimicrobial modulator, antileishmania, anxiolytic, anti-inflammatory, antinociceptive, and antioxidant. Even with important bioactive effects, the applicability of Riparin-A is limited due to its low solubility in water, impairing its dissolution in biological fluids. Thus, the objective of this study was to develop a nanohybrid based on Riparin-A and Laponite to obtain a better dissolution profile and evaluate its cytotoxic potential. (2) Methods: The formation of a hybrid system was highlighted by X-ray powder diffraction, infrared spectroscopy, and thermal analysis. Solubility, dissolution, and cytotoxicity studies were performed; (3) Results: An increase in the solubility and aqueous dissolution rate of Riparin-A was observed in the presence of clay. Diffractometric analysis of the hybrid system suggests the amorphization of Riparin-A, and thermal analyses indicated attenuation of decomposition and melting of the Riparin-A after interaction with clay. Furthermore, the nanosystem did not exhibit cytotoxic activity on normal and tumorigenic lines. (4) Conclusions: These results are promising for the development of the Riparin-A/Laponite nanosystem for therapeutic purposes, suggesting an increase in the range of possible routes of administration and bioavailability of this bioactive compound.
Collapse
Affiliation(s)
- Duanne Mendes Gomes
- Post Program on Pharmaceutical Sciences, Federal University of Piauí—UFPI, Teresina 64049-550, Piauí, Brazil; (D.M.G.)
| | - Lyghia Maria Araújo Meirelles
- Department of Pharmacy, Federal University of Piauí—UFPI, Teresina 64049-550, Piauí, Brazil
- Health and Quality of Life Research Laboratory (LAPESQV), University Center Santo Agostinho—UNIFSA, Teresina 64049-550, Piauí, Brazil
| | - Paulo Monteiro Araujo
- Post Program on Pharmaceutical Sciences, Federal University of Piauí—UFPI, Teresina 64049-550, Piauí, Brazil; (D.M.G.)
| | - Rayran Walter Ramos de Sousa
- Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí—UFPI, Teresina 64049-550, Piauí, Brazil (P.M.P.F.)
| | - Paulo Michel Pinheiro Ferreira
- Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí—UFPI, Teresina 64049-550, Piauí, Brazil (P.M.P.F.)
| | - Stanley Juan Chavez Gutierrez
- Post Program on Pharmaceutical Sciences, Federal University of Piauí—UFPI, Teresina 64049-550, Piauí, Brazil; (D.M.G.)
| | | | - Fernanda Nervo Raffin
- Post—Program on Development and Technological Innovation in Medications, Federal University of Rio Grande do Norte—UFRN, Natal 59012-570, Rio Grande do Norte, Brazil
| |
Collapse
|
2
|
Neuwirth LS, Verrengia MT, Harikinish-Murrary ZI, Orens JE, Lopez OE. Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization. Front Mol Neurosci 2022; 15:912146. [PMID: 36061362 PMCID: PMC9428565 DOI: 10.3389/fnmol.2022.912146] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 06/21/2022] [Indexed: 11/17/2022] Open
Abstract
Behavioral neuroscience tests such as the Light/Dark Test, the Open Field Test, the Elevated Plus Maze Test, and the Three Chamber Social Interaction Test have become both essential and widely used behavioral tests for transgenic and pre-clinical models for drug screening and testing. However, as fast as the field has evolved and the contemporaneous involvement of technology, little assessment of the literature has been done to ensure that these behavioral neuroscience tests that are crucial to pre-clinical testing have well-controlled ethological motivation by the use of lighting (i.e., Lux). In the present review paper, N = 420 manuscripts were examined from 2015 to 2019 as a sample set (i.e., n = ~20–22 publications per year) and it was found that only a meager n = 50 publications (i.e., 11.9% of the publications sampled) met the criteria for proper anxiogenic and anxiolytic Lux reported. These findings illustrate a serious concern that behavioral neuroscience papers are not being vetted properly at the journal review level and are being released into the literature and public domain making it difficult to assess the quality of the science being reported. This creates a real need for standardizing the use of Lux in all publications on behavioral neuroscience techniques within the field to ensure that contributions are meaningful, avoid unnecessary duplication, and ultimately would serve to create a more efficient process within the pre-clinical screening/testing for drugs that serve as anxiolytic compounds that would prove more useful than what prior decades of work have produced. It is suggested that improving the standardization of the use and reporting of Lux in behavioral neuroscience tests and the standardization of peer-review processes overseeing the proper documentation of these methodological approaches in manuscripts could serve to advance pre-clinical testing for effective anxiolytic drugs. This report serves to highlight this concern and proposes strategies to proactively remedy them as the field moves forward for decades to come.
Collapse
Affiliation(s)
- Lorenz S. Neuwirth
- Department of Psychology, SUNY Old Westbury, Old Westbury, NY, United States
- SUNY Neuroscience Research Institute, SUNY Old Westbury, Old Westbury, NY, United States
- *Correspondence: Lorenz S. Neuwirth
| | - Michael T. Verrengia
- Department of Psychology, SUNY Old Westbury, Old Westbury, NY, United States
- SUNY Neuroscience Research Institute, SUNY Old Westbury, Old Westbury, NY, United States
| | - Zachary I. Harikinish-Murrary
- Department of Psychology, SUNY Old Westbury, Old Westbury, NY, United States
- SUNY Neuroscience Research Institute, SUNY Old Westbury, Old Westbury, NY, United States
| | - Jessica E. Orens
- Department of Psychology, SUNY Old Westbury, Old Westbury, NY, United States
- SUNY Neuroscience Research Institute, SUNY Old Westbury, Old Westbury, NY, United States
| | - Oscar E. Lopez
- Department of Psychology, SUNY Old Westbury, Old Westbury, NY, United States
- SUNY Neuroscience Research Institute, SUNY Old Westbury, Old Westbury, NY, United States
| |
Collapse
|
3
|
Figueiredo KA, Magalhães Costa RK, Rocha JA, Chavez Gutierrez SJ, Ramos RM, Muálem de Moraes Alves M, Aécio de Amorim Carvalho F, Menezes Carvalho AL, Lima FDCA. Antileishmanial activity of Riparin structural analogs of Aniba riparia: Biological evaluation, in silico Adme-Tox, and molecular docking. Exp Parasitol 2022; 236-237:108257. [DOI: 10.1016/j.exppara.2022.108257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 03/17/2022] [Accepted: 04/03/2022] [Indexed: 11/25/2022]
|
4
|
Dias da Silva D, Silva JP, Carmo H, Carvalho F. Neurotoxicity of psychoactive substances: A mechanistic overview. CURRENT OPINION IN TOXICOLOGY 2021. [DOI: 10.1016/j.cotox.2021.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
5
|
Almeida AACD, Ferreira JRDO, de Carvalho RBF, Rizzo MDS, Lopes LDS, Dittz D, Castro E Souza JMD, Ferreira PMP. Non-clinical toxicity of (+)-limonene epoxide and its physio-pharmacological properties on neurological disorders. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2020; 393:2301-2314. [PMID: 32653979 DOI: 10.1007/s00210-020-01943-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Accepted: 07/06/2020] [Indexed: 12/13/2022]
Abstract
The compound (+)-limonene epoxide has antioxidant, anxiolytic, and antihelminthic properties. However, investigations to determine its long-term exposure were not performed. We investigated the systemic toxicological profile after chronic exposure as well as the antidepressant and antiepileptic potentialities of (+)-limonene epoxide on mice. Initially, we evaluated acute toxicity on Artemia salina nauplii and cytotoxicity on mice erythrocytes and peripheral blood mononuclear cells (PBMC). Aftterwards, mice were chronically treated for 120 days by gavage with (+)-limonene epoxide (25, 50, and 75 mg/kg/day) and this exposure was assessed by pathophysiological measurements. For antidepressant and anticonvulsivant analysis, we performed the forced swimming and tail suspension protocols and pentylenetetrazol- and picrotoxin-induced seizures, respectively. (+)-Limonene epoxide showed a LC50 value of 318.7 μg/mL on A. salina shrimps, caused lysis of red blood cells at higher concentrations only but did not show cytotoxicity on PMBC, which suggests pharmacological safety if plasma concentrations do not exceed 100 μg/mL. Macroscopic, hematological, clinical chemistry, and nutritional changes were not detected, though focal areas of hepatic necrosis, inflammatory infiltrate, and karyolysis have been detected at 75 mg/kg/day. The compound inhibited the developing of pentylenetetrazol- and picrotoxin-induced seizures, decreased deaths, and reduced immobility times, mainly at 75 mg/kg. So, it reversed reserpine effects, suggesting antidepressant effects should be linked to serotonergic and/or adrenergic transmission. It is feasible that (+)-limonene epoxide plays a benzodiazepine-like anticonvulsive action and may be also recommended as an antidote for poisonings caused by central depressants.
Collapse
Affiliation(s)
- Antonia Amanda Cardoso de Almeida
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, 64049-550, Brazil
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Universitária Avenue, Ininga, Teresina, Piauí, 64049-550, Brazil
| | | | | | | | - Luciano da Silva Lopes
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, 64049-550, Brazil
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Universitária Avenue, Ininga, Teresina, Piauí, 64049-550, Brazil
| | - Dalton Dittz
- Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, 64049-550, Brazil
| | - João Marcelo de Castro E Souza
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, 64049-550, Brazil
- Department of Biochemistry and Pharmacology, Federal University of Piauí, Teresina, 64049-550, Brazil
| | - Paulo Michel Pinheiro Ferreira
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, 64049-550, Brazil.
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Universitária Avenue, Ininga, Teresina, Piauí, 64049-550, Brazil.
| |
Collapse
|
6
|
Golzio Dos Santos S, Fernandes Gomes I, Fernandes de Oliveira Golzio AM, Lopes Souto A, Scotti MT, Fechine Tavares J, Chavez Gutierrez SJ, Nóbrega de Almeida R, Barbosa-Filho JM, Sobral da Silva M. Psychopharmacological effects of riparin III from Aniba riparia (Nees) Mez. (Lauraceae) supported by metabolic approach and multivariate data analysis. BMC Complement Med Ther 2020; 20:149. [PMID: 32416725 PMCID: PMC7229579 DOI: 10.1186/s12906-020-02938-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Accepted: 04/27/2020] [Indexed: 12/18/2022] Open
Abstract
Background Currently there is a high prevalence of humor disorders such as anxiety and depression throughout the world, especially concerning advanced age patients. Aniba riparia (Nees) Mez. (Lauraceae), popular known as “louro”, can be found from the Amazon through Guianas until the Andes. Previous studies have already reported the isolation of alkamide-type alkaloids such as riparin III (O-methyl-N-2,6-dyhydroxy-benzoyl tyramine) which has demonstrated anxiolytic and antidepressant-like effects in high doses by intraperitoneal administration. Methods Experimental protocol was conducted in order to analyze the anxiolytic-like effect of riparin III at lower doses by intravenous administration to Wistar rats (Rattus norvegicus) (n = 5). The experimental approach was designed to last 15 days, divided in 3 distinct periods of five days: control, anxiogenic and treatment periods. The anxiolytic-like effect was evaluated by experimental behavior tests such as open field and elevated plus-maze test, combined with urine metabolic footprint analysis. The urine was collected daily and analyzed by 1H NMR. Generated data were statistically treated by Principal Component Analysis in order to detect patterns among the distinct periods evaluated as well as biomarkers responsible for its distinction. Results It was observed on treatment group that cortisol, biomarker related to physiological stress was reduced, indicating anxiolytic-like effect of riparin III, probably through activation of 5-HT2A receptors, which was corroborated by behavioral tests. Conclusion 1H NMR urine metabolic footprint combined with multivariate data analysis have demonstrated to be an important diagnostic tool to prove the anxiolytic-like effect of riparin III in a more efficient and pragmatic way.
Collapse
Affiliation(s)
- Sócrates Golzio Dos Santos
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - Isis Fernandes Gomes
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | | | - Augusto Lopes Souto
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - Marcus Tullius Scotti
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - Josean Fechine Tavares
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - Stanley Juan Chavez Gutierrez
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - Reinaldo Nóbrega de Almeida
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - José Maria Barbosa-Filho
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil
| | - Marcelo Sobral da Silva
- Instituto de Pesquisa de Fármacos e Medicamentos - IPeFarM, Universidade Federal da Paraíba, João Pessoa, PB, 58051-900, Brazil.
| |
Collapse
|
7
|
Ferreira PMP, Machado KDC, Lavorato SN, Oliveira FDCED, Silva JDN, Almeida AACD, Santos LDS, Silva VR, Bezerra DP, Soares MBP, Pessoa C, Moraes Filho MOD, Ferreira JRDO, Sousa JMDCE, Maltarollo VG, Alves RJ. Pharmacological and physicochemical profile of arylacetamides as tools against human cancers. Toxicol Appl Pharmacol 2019; 380:114692. [PMID: 31356931 DOI: 10.1016/j.taap.2019.114692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Revised: 07/22/2019] [Accepted: 07/23/2019] [Indexed: 10/26/2022]
Abstract
Arylacetamides are widely used as synthetic intermediates to obtain medicinal substances. This work evaluated in vitro antiproliferative activity of ten 2-Chloro-N-arylacetamides on human normal and cancer cells and detailed in vivo toxicological and anticancer investigations. Initially, cytotoxic colorimetric assays were performed using tumor lines, peripheral blood mononuclear cells (PBMC) and erythrocytes. Compounds 2, 3 and 4 were tested for acute toxicity (50, 150 and 300 mg/kg) and for subacute antitumoral capacity in HCT-116 colon carcinoma-bearing xenograft mice for 15 days at 25 mg/kg/day. Most compounds revealed cytotoxic action on tumor lines and PBMC, but activity on human erythrocytes were not detected. Molecular dipole moment, lipophilicity and electronic constant of aryl substituents had effects upon in vitro antiproliferative capacity. More common in vivo acute behavioral signals with compounds 2, 3 and 4 were muscle relaxation, reduction of spontaneous locomotor activity and number of entries in closed arms and increased number of falls andtime spent in open arms, suggesting diazepam-like anxiolytic properties. Decrease of grabbing strength and overall activity were common, but palpebral ptosis and deaths occurred at 300 mg/kg only. Compounds 2 and 3 reduced colon carcinoma growth (21.2 and 27.5%, respectively, p < 0.05) without causing apparent signals of organ-specific toxicity after subacute exposure. The structural chemical simplicity of arylacetamides make them cost-effective alternatives and justifies further improvements to enhance activity, selectivity and the development of pharmaceutical formulations.
Collapse
Affiliation(s)
- Paulo Michel Pinheiro Ferreira
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Teresina 64049-550, Brazil; Postgraduate Programs in Pharmaceutical Sciences and Biotechnology, Federal University of Piauí, Teresina 64.049-550, Brazil.
| | - Kátia da Conceição Machado
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Teresina 64049-550, Brazil; Postgraduate Programs in Pharmaceutical Sciences and Biotechnology, Federal University of Piauí, Teresina 64.049-550, Brazil
| | - Stefânia Neiva Lavorato
- Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil; Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras 47808-021, Brazil
| | | | - Jurandy do Nascimento Silva
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Teresina 64049-550, Brazil; Postgraduate Programs in Pharmaceutical Sciences and Biotechnology, Federal University of Piauí, Teresina 64.049-550, Brazil
| | - Antonia Amanda Cardoso de Almeida
- Department of Biophysics and Physiology, Laboratory of Experimental Cancerology, Federal University of Piauí, Teresina 64049-550, Brazil; Postgraduate Programs in Pharmaceutical Sciences and Biotechnology, Federal University of Piauí, Teresina 64.049-550, Brazil
| | | | | | | | | | - Cláudia Pessoa
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza 60430-270, Brazil
| | - Manoel Odorico de Moraes Filho
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza 60430-270, Brazil
| | | | - João Marcelo de Castro E Sousa
- Postgraduate Programs in Pharmaceutical Sciences and Biotechnology, Federal University of Piauí, Teresina 64.049-550, Brazil; Department of Biology, Federal University of Piauí, Picos, Piauí 64067-670, Brazil
| | - Vinícius Gonçalves Maltarollo
- Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil
| | - Ricardo José Alves
- Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil
| |
Collapse
|